3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
35
Nivolumab
14
Docetaxel
11
atezolizumab
10
Paclitaxel
9
Carboplatin
7
Gemcitabine
6
Cisplatin
6
Trastuzumab
5
Magnetic Resonance Spectroscopy
5
Ipilimumab
5
Fluorodeoxyglucose F18
5
Cyclophosphamide
5
Bevacizumab
5
fludarabine
4
avelumab
4
Specimen Handling
4
Psychiatric Rehabilitation
4
Oxaliplatin
4
Leucovorin
4
Fluorouracil
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
cemiplimab
3
Taxes
3
Polymerase Chain Reaction
3
Pemetrexed
3
Irinotecan
3
Gene Expression Profiling
3
Early Intervention, Educational
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
Radionuclide Imaging
×
Genitourinary
×
Clear all
NCT06904365
2026-05-18
OvAR-Y
Washington University School of Medicine
Active not recruiting
10 enrolled